Current progress toward eradicatingHelicobacter pyloriin East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea
Author:
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (6) , 1493-502
Abstract
New 2013 guidelines on Helicobacter pylori (H. pylori) infection have been published in China, Japan, and South Korea. Like the previous ones, these new guidelines differ between the three countries with regard to the indications for H. pylori eradication, diagnostic methods, and treatment regimens. The most profound change among all of the guidelines is that the Japanese national health insurance system now covers the expenses for all infected subjects up to second-line treatment. This makes the Japanese indications for eradication much wider than those in China and South Korea. With regard to the diagnosis, a serum H. pylori antibody test is not recommended in China, whereas it is considered to be the most reliable method in Japan. A decrease relative to the initial antibody titer of more than 50% after 6-12 mo is considered to be the most accurate method for determining successful eradication in Japan. In contrast, only the urea breath test is recommended after eradication in China, while either noninvasive or invasive methods (except the bacterial culture) are recommended in South Korea. Due to the increased rate of antibiotics resistance, first-line treatment is omitted in China and South Korea in cases of clarithromycin resistance. Notably, the Japanese regimen consists of a lower dose of antibiotics for a shorter duration (7 d) than in the other countries. There is neither 14 d nor bismuth-based regimen in the first-line and second-line treatment in Japan. Such differences among countries might be due to differences in the approvals granted by the governments and national health insurance system in each country. Further studies are required to achieve the best results in the diagnosis and treatment of H. pylori infection based on cost-effectiveness in East Asian countries.Keywords
This publication has 60 references indexed in Scilit:
- Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapyJournal of Clinical Biochemistry and Nutrition, 2013
- Prevalence of Primary and Secondary Antimicrobial Resistance of Helicobacter pylori in Korea from 2003 through 2012Helicobacter, 2012
- Predictive Factors for Improvement of Atrophic Gastritis and Intestinal Metaplasia After Helicobacter Pylori Eradication: A Three‐Year Follow‐Up Study in KoreaHelicobacter, 2012
- Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in JapanJournal of Gastroenterology, 2012
- Effect of Helicobacter pylori Eradication on the Development of Refl ux Esophagitis and Gastroesophageal Refl ux Symptoms: A Nationwide Multi-Center Prospective StudyGut and Liver, 2011
- High Efficacy of 14‐Day Triple Therapy‐Based, Bismuth‐Containing Quadruple Therapy for Initial Helicobacter pylori EradicationHelicobacter, 2010
- Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levelsInternational Journal of Cancer, 2009
- Decreasing prevalence of Helicobacter pylori infection: a 9-year observational study.2007
- Gastric Acidity in Patients with Follicular Gastritis is Significantly Reduced, but Can be Normalized After Eradication for Helicobacter pyloriHelicobacter, 2005
- Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese populationJournal of Gastroenterology, 2004